findmyKOL
Clinical trialNCT06353997RecruitingPhase 2Interventional

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

SponsorProvidence Health & ServicesEnrollment12Triple Negative Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase II trial to assess efficacy and feasibility of pembrolizumab + INBRX-106 as an induction therapy preceding neoadjuvant therapy.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Ellison Institute of Technology (eitm)

    Los Angeles, California, United States

    Recruiting
  • Providence Portland Cancer Institute - Franz Clinic

    Portland, Oregon, United States

    Alison Conlin, MDAmy Hartman, NPEvelyn Brosnan, MDEvie Hobbs, MDKathleen Dronkowski, NPKimberlie Dame, NPMolly Davis, NPRaYoung Chung, NPRoxanne Griswold, NPRui Li, MD, PhDSasha Stanton, MD, PhDZheng Topp, MD
    Recruiting
  • Providence St. Vincent Medical Center

    Portland, Oregon, United States

    David Page, MD
    Recruiting
  • Swedish Cancer Institute

    Seattle, Washington, United States

    Not, yet, recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

INBRX-106Pembrolizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
5 Sept 2024
Primary completion
30 Jun 2027
Completion
30 Jun 2029
Last update posted
15 Jan 2026
Registered enrollment
12
Registry id
NCT06353997
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.